Tobias Financial Advisors Inc. Increases Position in Johnson & Johnson (NYSE:JNJ)

Tobias Financial Advisors Inc. increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,529 shares of the company’s stock after buying an additional 87 shares during the quarter. Tobias Financial Advisors Inc.’s holdings in Johnson & Johnson were worth $734,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in JNJ. Fiduciary Family Office LLC boosted its position in shares of Johnson & Johnson by 11.6% during the third quarter. Fiduciary Family Office LLC now owns 9,654 shares of the company’s stock worth $1,564,000 after buying an additional 1,004 shares during the period. Falcon Wealth Planning lifted its holdings in Johnson & Johnson by 5.9% during the 3rd quarter. Falcon Wealth Planning now owns 2,852 shares of the company’s stock worth $462,000 after buying an additional 158 shares in the last quarter. Crestwood Advisors Group LLC grew its stake in shares of Johnson & Johnson by 1.0% in the third quarter. Crestwood Advisors Group LLC now owns 391,942 shares of the company’s stock worth $63,518,000 after acquiring an additional 3,701 shares in the last quarter. Global Wealth Management Investment Advisory Inc. boosted its holdings in Johnson & Johnson by 7.9% in the third quarter. Global Wealth Management Investment Advisory Inc. now owns 31,786 shares of the company’s stock valued at $5,151,000 after purchasing an additional 2,325 shares during the period. Finally, Heritage Investors Management Corp raised its position in Johnson & Johnson by 0.9% in the 3rd quarter. Heritage Investors Management Corp now owns 173,223 shares of the company’s stock valued at $28,073,000 after purchasing an additional 1,623 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of analyst reports. Citigroup raised their price target on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Morgan Stanley increased their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Finally, Wells Fargo & Company upped their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Six investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $175.93.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $158.35 on Wednesday. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The firm has a market capitalization of $381.25 billion, a price-to-earnings ratio of 22.92, a price-to-earnings-growth ratio of 2.84 and a beta of 0.53. The business’s 50 day simple moving average is $163.09 and its 200-day simple moving average is $155.75. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period last year, the firm posted $2.66 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.13%. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.